Used in pharmaceutical research as a key intermediate in the synthesis of targeted protein degraders, particularly PROTACs (Proteolysis Targeting Chimeras). It links E3 ligase ligands to target protein binders, enabling selective degradation of disease-related proteins. Its structure supports the formation of bifunctional molecules that recruit cereblon E3 ubiquitin ligase, leading to ubiquitination and subsequent degradation of specific cellular proteins by the proteasome. Commonly applied in the development of anticancer agents and treatments for inflammatory and neurodegenerative diseases.